Basel (Switzerland) and Mannheim (Germany), September 12, 2019 – VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, announced today that the Company will participate in several events around the globe in the coming months. Company representatives will be available for networking and one-on-one meetings at the following conferences:
3rd Annual China Cross-Border Healthcare Investment Summit
September 17-20, 2019
Hangzhou & Chengdu, China
Dr. Heinz Lubenau, Chief Operating Officer & Co-Founder of VAXIMM, will give corporate presentations and participate in one-on-one meetings with top-tier Chinese healthcare investors. The program can be found here.
5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
September 25-28, 2019
VAXIMM representatives will be available for one-on-one meetings during the conference. To schedule a meeting, please contact email@example.com.
25th Annual International Partnering Conference BIO-Europe®
November 11-13, 2019
VAXIMM plans to give a corporate presentation and host one-on-one meetings at this event. To request a meeting, please sign up through the event’s partneringONE meeting system.
Jefferies 2019 London Healthcare Conference
November 20-21, 2019
Management will be available for one-on-one meetings.
4th Annual NeoAg Summit
November 20-22, 2019
Dr. Lubenau will give a presentation entitled, “Oral T-Cell Therapies for Personalized Neoantigen-Targeting Treatment,” during the session, “Clinical & Translational – Interrogating the Best Manufacturing Platforms to Reduce Needle to Needle Time,” on November 22 at 11 AM ET. The program can be found here.
VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor. The Company has a pipeline of complementary development candidates targeting different tumor structures. The most advanced product candidate, oral VXM01, activates killer T-cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including brain cancer. VAXIMM also has a neoantigen program (VXM NEO) currently in preclinical development; the Company’s platform allows for the fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by other neoantigen approaches. VAXIMM has a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs. CMS has made an equity investment in VAXIMM; the Company’s other investors include BB Biotech Ventures, M Ventures, Sunstone Capital and BioMed Partners. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities. For more information, please see www.vaximm.com.
Dr. Heinz Lubenau
Tel.: +49 621 8359 687 0
MC Services AG
Katja Arnold, Laurie Doyle
Tel: +49 89 210228 0